(Q80295712)

PubMed ID

16985579

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985579%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

1 reference

1 reference

1

Shahrokh F Shariat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

author name string

Eduardo I Canto

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

Michael W Kattan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

Kevin M Slawin

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

publication date

1 January 2004

1 reference

PubMed ID

16985579

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985579%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

page(s)

58-72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume

10 May 2020

cites work

1 reference

12 December 2020

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

1 reference

12 December 2020

Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis

1 reference

12 December 2020

Interleukin-6 is an autocrine growth factor in human prostate cancer.

1 reference

12 December 2020

Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2.

1 reference

12 December 2020

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 reference

12 December 2020

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

12 December 2020

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146

1 reference

12 December 2020

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

1 reference

12 December 2020

Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis

1 reference

12 December 2020

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

1 reference

12 December 2020

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy

1 reference

12 December 2020

Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer

1 reference

12 December 2020

Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid

1 reference

12 December 2020

Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro

1 reference

12 December 2020

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

12 December 2020

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study

1 reference

12 December 2020

Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications

1 reference

12 December 2020

Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model

1 reference

12 December 2020

Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas

1 reference

12 December 2020

Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation

1 reference

12 December 2020

Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma

1 reference

12 December 2020

Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells

1 reference

12 December 2020

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

12 December 2020

Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer

1 reference

12 December 2020

A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer

1 reference

12 December 2020

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

12 December 2020

Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations

1 reference

12 December 2020

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

12 December 2020

Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate

1 reference

12 December 2020

Cytokine variations in patients with hormone treated prostate cancer

1 reference

12 December 2020

Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy

1 reference

12 December 2020

Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors

1 reference

12 December 2020

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.

1 reference

12 December 2020

Free prostate-specific antigen in serum is becoming more complex

1 reference

12 December 2020

Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis

1 reference

12 December 2020

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

1 reference

12 December 2020

Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy

1 reference

12 December 2020

Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study

1 reference

12 December 2020

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

12 December 2020

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

12 December 2020

Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer

1 reference

12 December 2020

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

12 December 2020

Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy

1 reference

12 December 2020

Prostate-specific antigen and prostate gland volume: Correlation and clinical application

1 reference

12 December 2020

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

1 reference

12 December 2020

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer

1 reference

12 December 2020

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

1 reference

12 December 2020

Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer

1 reference

12 December 2020

Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia

1 reference

12 December 2020

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

12 December 2020

International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

1 reference

12 December 2020

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer

1 reference

12 December 2020

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.

1 reference

12 December 2020

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

1 reference

12 December 2020

Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer

1 reference

12 December 2020

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

1 reference

12 December 2020

Interleukin-6: a candidate mediator of human prostate cancer morbidity

1 reference

12 December 2020

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml

1 reference

12 December 2020

Characterization of the role of IL-6 in the progression of prostate cancer

1 reference

12 December 2020

Serum interleukin 6 as a prognostic factor in patients with prostate cancer

1 reference

12 December 2020

Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial

1 reference

12 December 2020

Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin

1 reference

12 December 2020

Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen

1 reference

12 December 2020

Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer

1 reference

12 December 2020

The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease1

1 reference

12 December 2020

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

1 reference

12 December 2020

Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers

1 reference

12 December 2020

Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study

1 reference

12 December 2020

Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen

1 reference

12 December 2020

Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy

1 reference

12 December 2020

Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.

1 reference

12 December 2020

Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression

1 reference

12 December 2020

Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project

1 reference

12 December 2020

Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen

1 reference

12 December 2020

Longitudinal screening for prostate cancer with prostate-specific antigen

1 reference

12 December 2020

The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA

1 reference

12 December 2020

Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

1 reference

12 December 2020

Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients

1 reference

12 December 2020

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

1 reference

12 December 2020

The new human tissue kallikrein gene family: structure, function, and association to disease.

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472815&resulttype=core&format=json

10 May 2020

1 reference